These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 28881714)
1. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Fenoglio R; Baldovino S; Menegatti E Oncotarget; 2017 Aug; 8(32):52072-52077. PubMed ID: 28881714 [TBL] [Abstract][Full Text] [Related]
2. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis. Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432 [TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362 [TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054 [TBL] [Abstract][Full Text] [Related]
5. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Timlin H; Lee SM; Manno RL; Seo P; Geetha D Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088 [TBL] [Abstract][Full Text] [Related]
7. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808 [TBL] [Abstract][Full Text] [Related]
9. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L; J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438 [TBL] [Abstract][Full Text] [Related]
10. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. Saito A; Takeuchi Y; Kagaya S; Ojima Y; Fukami H; Sato H; Matsuda K; Nagasawa T Tohoku J Exp Med; 2017 May; 242(1):53-62. PubMed ID: 28539536 [TBL] [Abstract][Full Text] [Related]
11. Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Alberici F; Jayne DR Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571 [TBL] [Abstract][Full Text] [Related]
12. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC; J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429 [TBL] [Abstract][Full Text] [Related]
13. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956 [TBL] [Abstract][Full Text] [Related]
15. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028 [TBL] [Abstract][Full Text] [Related]
16. Targeted immunotherapy strategies in ANCA-associated vasculitis. Puéchal X Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478 [TBL] [Abstract][Full Text] [Related]
17. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study. Azar L; Springer J; Langford CA; Hoffman GS Arthritis Rheumatol; 2014 Oct; 66(10):2862-70. PubMed ID: 24943239 [TBL] [Abstract][Full Text] [Related]
18. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's). Recillas-Gispert C; Serna-Ojeda JC; Flores-Suárez LF Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2279-84. PubMed ID: 26507398 [TBL] [Abstract][Full Text] [Related]
19. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L; Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319 [TBL] [Abstract][Full Text] [Related]
20. Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis. Wawrzycka-Adamczyk K; Zugaj A; Włudarczyk A; Kosałka J; Sznajd J; Bazan-Socha S; Musiał J Przegl Lek; 2014; 71(12):663-5. PubMed ID: 25951692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]